Holen Sie sich die Stockscreener-App
282.80
1.90%
-5.49
Schlusskurs vom Vortag:
$288.29
Offen:
$276.35
24-Stunden-Volumen:
1.39M
Relative Volume:
2.58
Marktkapitalisierung:
$19.84B
Einnahmen:
$1.98B
Nettoeinkommen (Verlust:
$420.90M
KGV:
48.42
EPS:
5.84
Netto-Cashflow:
$218.20M
1W Leistung:
+0.80%
1M Leistung:
+2.43%
6M Leistung:
+52.21%
1J Leistung:
+46.92%
1-Tages-Spanne:
$274.87
$286.66
1-Wochen-Bereich:
$270.00
$288.95
52-Wochen-Spanne:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
282.80 | 19.84B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Insulet Q4 2024 revenue up 17.2% to USD 597.5M - Medical Buyer
Insulet Stock: Aiding Patients And Investors (NASDAQ:PODD) - Seeking Alpha
Insulet Earnings: What To Look For From PODD - MSN
Insulet’s Earnings Highlight Omnipod Success Amid Challenges - TipRanks
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst - Benzinga
Insulet stock price target raised to $293 by Stifel - Investing.com Canada
Stifel Nicolaus Adjusts Insulet Price Target to $293 From $245 -February 21, 2025 at 09:21 am EST - Marketscreener.com
Leerink Partners Adjusts Insulet Price Target to $314 From $278 -February 21, 2025 at 09:19 am EST - Marketscreener.com
Assessing Insulet: Insights From 6 Financial Analysts - Benzinga
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise - Yahoo Finance
Insulet Corporation (NASDAQ:PODD) Q4 2024 Earnings Call Transcript - Insider Monkey
Insulet stock target raised to $324 by Canaccord Genuity - Investing.com South Africa
Insulet Corporation (PODD) PT Raised to $293 at Stifel - StreetInsider.com
Insulet stock price target raised to $310 by BTIG - Investing.com South Africa
Insulet Corporation (PODD) PT Raised to $324 at Canaccord Genuity - StreetInsider.com
Insulet Updates Equity Agreements for Fiscal 2025 - TipRanks
INSULET CORP SEC 10-K Report - TradingView
Insulet Corporation (PODD) PT Raised to $310 at BTIG - StreetInsider.com
Blue Owl Capital, Insulet, Unity Software - TradingView
Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Amidst Challenges - GuruFocus.com
Insulet’s Revenue Surpasses $2 Billion with Strong Growth - TipRanks
Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year - BioSpace
Insulet: Q4 Earnings Snapshot - Thehour.com
Earnings call transcript: Insulet beats Q4 2024 forecasts, stock dips By Investing.com - Investing.com Canada
Insulet earnings beat by $0.12, revenue topped estimates - Investing.com
Insulet Corp (PODD) Q4 Earnings: EPS of $1.39 Beats Estimate, Revenue Surpasses Expectations at $597.5 Million - GuruFocus.com
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Insulet (PODD) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Insulet Corporation (NASDAQ:PODD) Reports Strong Q4 2024 PerformanceNews and Statistics - IndexBox, Inc.
Insulet beats quarterly profit estimates on insulin pump demand - Reuters
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations - Yahoo Finance
Insulet: Q4 Earnings Snapshot -February 20, 2025 at 04:34 pm EST - Marketscreener.com
Insulet beats Q4 estimates, sees strong 2025 growth By Investing.com - Investing.com Australia
Insulet beats Q4 estimates, sees strong 2025 growth - Investing.com
Insulet Q4 Adjusted EPS Decreases, Revenue Rises -February 20, 2025 at 04:11 pm EST - Marketscreener.com
Agree To Purchase Insulet Corp At $200, Earn 36.5% Annualized Using Options - Nasdaq
Insulet Earnings: What To Look For From PODD By Stock Story - Investing.com Canada
(PODD) Trading Report - Stock Traders Daily
Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital - Simply Wall St
Certuity LLC Invests $245,000 in Insulet Co. (NASDAQ:PODD) - MarketBeat
Summit Trail Advisors LLC Acquires Shares of 1,882 Insulet Co. (NASDAQ:PODD) - MarketBeat
Sumitomo Mitsui DS Asset Management Company Ltd Grows Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
PODDInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - br.ADVFN.com
Choreo LLC Decreases Stock Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Insulet Co. (NASDAQ:PODD) Stake Boosted by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Insulet Co. (NASDAQ:PODD) Shares Sold by Stephens Investment Management Group LLC - MarketBeat
Insulet Corporation vs Menarini Diagnostics and EOFlow - Solicitors Journal
Tubeless Insulin Pumps Market to Grow with Leading Key Players - openPR
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):